Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Gross Margin (2024 - 2025)

Celldex Therapeutics (CLDX) has 5 years of Gross Margin data on record, last reported at 914.88% in Q4 2025.

  • For Q4 2025, Gross Margin fell 87751.0% year-over-year to 914.88%; the TTM value through Dec 2025 reached 288.16%, down 30823.0%, while the annual FY2025 figure was 288.16%, 30823.0% down from the prior year.
  • Gross Margin reached 914.88% in Q4 2025 per CLDX's latest filing, down from 105800.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 105800.0% in Q3 2025 and bottomed at 914.88% in Q4 2025.